Browsing Tag
European Commission
160 posts
AbbVie and Genmab’s TEPKINLY approved by EC for advanced lymphoma
AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have announced that the European Commission (EC) has granted conditional marketing…
EC approves Bunge’s $34bn acquisition of Viterra with conditions
The European Commission (EC) has granted unconditional approval for Bunge Global S.A.’s acquisition of Viterra Limited, a deal…
EC approves Hewlett Packard Enterprise’s acquisition of Juniper Networks
The European Commission (EC) has granted unconditional approval for Hewlett Packard Enterprise Company (HPE) to acquire Juniper Networks,…
Johnson & Johnson’s TB drug SIRTURO receives full approval from FDA and EC
In a significant development for the treatment of drug-resistant tuberculosis (TB), Johnson & Johnson has announced that SIRTURO…
EC endorses €10.8 French offshore wind energy scheme
The European Commission (EC) has granted approval for a monumental €10.82 billion scheme to support France’s ambitious offshore…
Voydeya approved in EU for enhanced treatment of PNH with residual haemolytic anaemia
Voydeya (danicopan), a first-in-class oral Factor D inhibitor from Alexion, AstraZeneca Rare Disease, has received approval from the…
European Commission approves Illumina’s divestment plan for GRAIL
The European Commission, exercising its authority under the EU Merger Regulation (EUMR), has granted approval to Illumina’s proposed…
Arcturus Therapeutics’ ARCT-032 gets EU’s orphan medicinal product designation for cystic fibrosis
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a leading global clinical-stage messenger RNA medicines company, has achieved a significant…
Fusion Pharmaceuticals secures rights for advanced prostate cancer treatment from Heidelberg University and Euratom
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a trailblazer in the oncology sector specializing in the development of next-generation radiopharmaceuticals,…
Biogen’s SKYCLARYS becomes first approved treatment for Friedreich’s Ataxia in EU
In a landmark decision, the European Commission (EC) has authorized Biogen Inc.’s SKYCLARYS (omaveloxolone) for the treatment of…